Table 1. Characteristics of participants vaccinated and unvaccinated for SARS-CoV-2.
| Characteristic | Total (n=947) | Unvaccinated (n=606, 64.0%) | Vaccinated (n=341, 36.0%) | P |
|---|---|---|---|---|
| Age (years), n (%) | 0.049 | |||
| <30 | 11 (1.2) | 8 (1.3) | 3 (0.9) | |
| 30–39 | 174 (18.4) | 128 (21.1) | 46 (13.5) | |
| 40–49 | 395 (41.7) | 248 (40.9) | 147 (43.1) | |
| 50–60 | 309 (32.6) | 186 (30.7) | 123 (36.1) | |
| >60 | 58 (6.1) | 36 (5.9) | 22 (6.5) | |
| Education, n (%) | 0.109 | |||
| Primary/middle school | 386 (40.8) | 247 (40.8) | 139 (40.8) | |
| High school | 264 (27.9) | 157 (25.9) | 107 (31.4) | |
| College or above | 297 (31.4) | 202 (33.3) | 95 (27.9) | |
| Marital status, n (%) | 0.284 | |||
| Unmarried | 18 (1.9) | 13 (2.1) | 5 (1.5) | |
| Married | 848 (89.5) | 534 (88.1) | 314 (92.1) | |
| Divorced | 60 (6.3) | 43 (7.1) | 17 (5.0) | |
| Widowed | 21 (2.2) | 16 (2.6) | 5 (1.5) | |
| Current treatment, n (%) | <0.001 | |||
| CT | 75 (7.9) | 60 (9.9) | 15 (4.4) | |
| TT | 52 (5.5) | 50 (8.3) | 2 (0.6) | |
| RT | 13 (1.4) | 13 (2.1) | 0 | |
| ET | 540 (57.0) | 319 (52.6) | 221 (64.8) | |
| CMT | 51 (5.4) | 31 (5.1) | 20 (5.9) | |
| ≥ Two therapy methods | 79 (8.3) | 72 (11.9) | 7 (2.1) | |
| NT | 137 (14.5) | 61 (10.1) | 76 (22.3) | |
| Comorbidities, n (%) | 0.194 | |||
| Hypertension | 90 (9.5) | 52 (8.6) | 38 (11.1) | |
| Hyperlipidemia | 81 (8.6) | 46 (7.6) | 35 (10.3) | |
| Obesity | 49 (5.2) | 30 (5.0) | 19 (5.6) | |
| Digestive diseases | 40 (4.2) | 29 (4.8) | 11 (3.2) | |
| Hepatitis | 36 (3.8) | 28 (4.6) | 8 (2.3) | |
| Respiratory diseases | 31 (3.3) | 20 (3.3) | 11 (3.2) | |
| Time since surgery, n (%) | <0.001 | |||
| <1 year | 317 (33.5) | 290 (47.9) | 27 (7.9) | |
| 1–2 years | 208 (22.0) | 160 (26.4) | 48 (14.1) | |
| 2–5 years | 305 (32.2) | 125 (20.6) | 180 (52.8) | |
| >5 years | 117 (12.4) | 31 (5.1) | 86 (25.2) | |
| Consult a doctor, n (%) | 639 (67.5) | 401 (66.2) | 238 (69.8) | 0.253 |
| Anxiety (GAD-2 ≥3) , n (%) | 72 (7.6) | 56 (9.2) | 16 (4.7) | 0.011 |
| Depression (PHQ-2 ≥3) , n (%) | 84 (8.9) | 68 (11.2) | 16 (4.7) | 0.001 |
CT, chemotherapy; TT, HER2-targeted therapy (such as: trastuzumab, pertuzumab, and pyrotinib, among others); RT, radiation therapy; ET, endocrine therapy (such as tamoxifen, toremifene, anastrozole, exemestane); CMT, Chinese medicine treatment; NT, not receiving a treatment; Comorbidities, other diseases besides breast cancer; 1–2 years, including the second year after surgery; 2–5 years, the second year after surgery is not included; Consult a doctor, consult a breast doctor or oncologist before COVID-19 vaccination; GAD-2, 2-item Generalized Anxiety Disorder scale; PHQ-2, 2-item Patient Health Questionnaire.